EyePoint Pharmaceuticals, Inc. — Director's Dealing 2021

Jun 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2021-06-22

Reporting Person: Jones David Scott (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-22	Restricted Stock Units	$0.00	A	14900.00	Acquired		Common Stock (14900.00)	Direct
2021-06-22	Stock Option (Right to Buy)	$13.13	A	60300.00	Acquired	2031-02-09	Common Stock (60300.00)	Direct

Footnotes

F1: The restricted stock units will vest in three ratable annual installments beginning February 9, 2022.

F2: The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2022 and the remainder ratably, on a monthly basis, over the remaining three years.